Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Coripharma is pleased to announce the successful completion of a pivotal bioequivalence (BE) study for Binimetinib tablets. The study demonstrated bioequivalence to the reference product, representing a key milestone in the development of this important oncology therapy for the generic market.

The successful outcome of the pivotal BE study confirms the robustness of Coripharma’s formulation and development strategy and supports the advancement of Binimetinib toward regulatory submission planned for October 2026.

Coripharma is currently evaluating strategic partnership opportunities for Binimetinib tablets to join our planned submission. We welcome discussions with partners with complementary regulatory, commercial, or market access capabilities in priority territories.

Binimetinib is an orally administered MEK inhibitor. The reference product (Mektovi®) is indicated in combination with encorafenib for the treatment of melanoma.

Pivotal BE Study Completed for Binimetinib Tablets. Submission planned for October.

Coripharma is pleased to announce changes within its Commercial Operations that further strengthen the company’s Business Development organization.

Harpa Leifsdottir has been appointed Department Manager of Business Development. Harpa has been part of Coripharma for five years, most recently as Business Development Manager, and brings more than 20 years of experience from the pharmaceutical industry. In her new role, she will continue to support Coripharma’s growth strategy and will report to Lilja Valdimarsdottir, Director of Commercial Operations.

In addition, Coripharma welcomes Rhys Thomas to the Business Development team. Rhys brings extensive international experience across global and regional business development, licensing and supply agreements, strategic alliances, and M&A, with a strong track record of delivering value‑creating partnerships.

These appointments reflect Coripharma’s continued focus on strengthening its commercial capabilities and supporting long‑term growth.

Coripharma Expands and Strengthens the Business Development Team

Coripharma is pleased to announce the successful completion of a pivotal bioequivalence (BE) study for Letermovir tablets. The study demonstrated bioequivalence to the reference product, representing a key milestone in the development of this important antiviral therapy for the generic market.

The successful outcome of the pivotal BE study confirms the robustness of Coripharma’s formulation and development strategy and supports the advancement of Letermovir toward regulatory submission.

Building on its established track record in the development of complex and hard‑to‑develop generic medicines, Coripharma is evaluating strategic partnership opportunities for Letermovir tablets.

The company is open to discussions with partners who bring complementary regulatory, commercial, or market access capabilities and who share Coripharma’s focus on the disciplined, long‑term development of high‑quality generic products.

Letermovir is an antiviral agent indicated for the prophylaxis of cytomegalovirus reactivation. The availability of a generic version of Letermovir has the potential to improve patient access while supporting sustainable healthcare systems.

Coripharma Successfully Completes Pivotal Bioequivalence Study for Letermovir

“I am delighted to have been offered this opportunity. Coripharma is a fantastic company with highly specialized and competent employees, and I look forward to taking on new challenges, working with the team and contributing together to the growth of the company”.

Thorey Jonsdottir, HR Director, said:

Thorey, who brings more than 10 years of HR experience to the role, said she’s looking forward to developing an HR approach that continues to support the wider business strategy. A seasoned HR professional, Thorey was previously Director of Human Resources and Training at Airport Associates at Keflavik International Airport and before that HR manager at General Electric – Oil and Gas in Oslo, Norway.

“We’re very happy to welcome Thorey to her new role as HR Director. The greatest asset of Coripharma are the professional and experienced individuals within the company so we’re really looking forward, with the guidance and support of Thorey, to further grow and develop our team”.

Jonina Gudmundsdottir, CEO at Coripharma, said:

Thorey Jonsdottir has been appointed a HR Director of Coripharma and will take a seat in the Executive Management Team in the award-winning company, further investing in its people and teams to add even more value to the services it provides. 

Coripharma has appointed a HR Director as growth in demand continues to drive expansion

About us

Services

Sustainability

Careers

Coripharma has appointed a HR Director as growth in demand continues to drive expansion

Thorey Jonsdottir, HR Director, said:

Thorey Jonsdottir, HR Director, said:

Jonina Gudmundsdottir, CEO at Coripharma, said:

Jonina Gudmundsdottir, CEO at Coripharma, said:

More news

Pivotal BE Study Completed for Binimetinib Tablets. Submission planned for October.

Coripharma Expands and Strengthens the Business Development Team

Coripharma Successfully Completes Pivotal Bioequivalence Study for Letermovir

+354 4206700